US Stock MarketDetailed Quotes
KPTI Karyopharm Therapeutics
- 0.903
- -0.087-8.75%
Close Nov 1 16:00 ET
- 0.978
- +0.075+8.27%
Pre 06:43 ET
112.61MMarket Cap-792P/E (TTM)
1.020High0.880Low1.70MVolume0.990Open0.990Pre Close1.66MTurnover1.50%Turnover RatioLossP/E (Static)124.68MShares1.95052wk High-0.85P/B102.32MFloat Cap0.61752wk Low--Dividend TTM113.28MShs Float49.005Historical High--Div YieldTTM14.10%Amplitude0.617Historical Low0.975Avg Price1Lot Size
Karyopharm Therapeutics Key Stats
EPS
According to the latest financial report of Karyopharm Therapeutics, the latest earnings per share (TTM) for the company is -0.20. Investing in companies with strong earnings per share can potentially provide higher returns.
Currency: USD
Quarterly
Loading...
FCF
Interested in knowing about Karyopharm Therapeutics's free cash flow? The latest report shows it as -38.50M. Keep an eye on and closely monitor the company's cash flow to make informed investment decisions.
Currency: USD
Quarterly
Loading...
Current Ratio
If you are evaluating a company's liquidity, current ratio is an important measure to consider. The latest financial report of Karyopharm Therapeutics shows that the company's current ratio is 3.62, indicating healthy liquidity.
Currency: USD
Quarterly
Loading...
Quick Ratio
Another liquidity indicator to closely monitor is quick ratio. According to the latest financial results of Karyopharm Therapeutics, the quick ratio is 3.30, indicating that the company can meet its short-term debt obligations.
Currency: USD
Quarterly
Loading...
ROE
Want to learn more about the financial health of Karyopharm Therapeutics? The latest ROE figure is -1.05K%, indicating that the company has stable profitability.
Currency: USD
Quarterly
Loading...
ROA
Investors looking for profitability indicators may be interested in ROA. According to the latest financial results of Karyopharm Therapeutics, the total asset return on investment (ROA) is 8.72%.
Currency: USD
Quarterly
Loading...
Gross Margin
Gross margin can provide insight into a company's pricing strategy and cost structure. Check Karyopharm Therapeutics's latest financial report to see how their gross margin is doing - currently at 96.58%.
Currency: USD
Quarterly
Loading...
Net Margin
For investors focusing on operational efficiency, net profit margin is an important indicator. According to the latest financial results of Karyopharm Therapeutics, the net profit margin is 55.61%, which is a good sign for its profitability.
Currency: USD
Quarterly
Loading...
Analysis
Price Target
No Data
Heat List
US
Overall
Symbol
Latest Price
% Chg
No Data